SCHEMBL3867722

SCHEMBL3867722

CCOCc1nc2c(N)nc3cc(/C=C/c4cccnc4)ccc3c2n1CCCOC

nearest known ligand 0.49

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 15/20 0.49
TLR7 Q9NYK1 18/20 0.49
NUDT1 P36639 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3867728 1.00 TLR8 (0.49) TLR8TLR7NUDT1
SCHEMBL3861434 0.87 TLR8 (0.51) TLR8TLR7NUDT1
SCHEMBL3861440 0.87 TLR8 (0.51) TLR8TLR7NUDT1
SCHEMBL3871201 0.86 TLR7 (0.65) TLR8TLR7NUDT1
SCHEMBL3871208 0.86 TLR7 (0.65) TLR8TLR7NUDT1
SCHEMBL13645717 0.85 TLR8 (0.53) TLR8TLR7NUDT1
SCHEMBL3867611 0.85 TLR7 (0.66) TLR8TLR7NUDT1
SCHEMBL3867603 0.85 TLR7 (0.66) TLR8TLR7NUDT1
SCHEMBL3871193 0.83 TLR7 (0.49) TLR8TLR7NUDT1
SCHEMBL3871188 0.83 TLR7 (0.49) TLR8TLR7NUDT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598382-B2 Aryl substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-10-06 US disclosed
US-7598382-B2 Aryl substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-10-06 US disclosed
US-7598382-B2 Aryl substituted imidazoquinolines COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-10-06 US disclosed
US-7091214-B2 Aryl substituted Imidazoquinolines 3M INNOVATIVE PROPERTIES CO. (US) 2006-08-15 US disclosed
US-20060111387-A1 ARYL SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111387-A1 ARYL SUBSTITUTED IMIDAZOQUINOLINES IL2, IFNG, IRF3 TLR8 220/4885TLR7 68/4885NUDT1 648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.